Drug intelligence / Profile preview

LY2787106

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LY2787106 is a fully humanized monoclonal antibody that targets the peptide hormone hepcidin. By binding to and neutralizing hepcidin, it prevents ferroportin internalization and restores iron efflux from cells, thereby allowing transferrin-mediated iron transport to the bone marrow. This mechanism is intended to counteract anemia associated with cancer by mobilizing iron stores for erythropoiesis. The drug was developed by Eli Lilly and Company as an antianaemic agent but development was discontinued after phase 1 clinical trials in patients with cancer-associated anemia[1][3][4][5][6].

Other names: anti-hepcidin monoclonal antibody LY2787106

Targets

HAMP (Hepcidin)

Beyond the preview

Go deeper on LY2787106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2787106.

Explore the full profile